CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC
NCT05724355
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG:
Dalpiciclib Isetionate Tablets, Camrelizumab
Sponsor
Sun Yat-sen University